The ABCC1 Knockout HT29 Polyclonal Cells product provides a ready-to-use CRISPR/Cas9-edited polyclonal HT29 cell population in which the ABCC1 gene has been disrupted. This genetically modified pool of cells serves as a loss-of-function model for investigating the biological roles of the ABCC1-encoded multidrug resistance protein 1 (MRP1). Unlike clonal cell lines, the polyclonal format preserves population-level heterogeneity while eliminating target-gene function, making it suitable for studies that require a broadly representative knockout background without the potential artifacts of single-cell cloning.
The HT29 host cell line is an epithelial cell model derived from a human colorectal adenocarcinoma. These cells are extensively used in oncology research as a representative colorectal cancer line, particularly for investigations into tumor biology, drug response, and resistance mechanisms. HT29 cells retain key features of their tumor origin, including adherent growth and the capacity for differentiation, and they serve as a robust platform for gene-editing studies aimed at dissecting the molecular bases of colorectal carcinoma.
ABCC1 encodes MRP1, an ATP-dependent efflux transporter that mediates the cellular extrusion of a wide range of xenobiotics, glutathione conjugates, glucuronides, and signaling lipids such as leukotriene C4 and sphingosine-1-phosphate. Its activity is controlled by upstream regulators including the transcription factors NRF2, MYC, and p53, as well as cellular stress conditions like oxidative stress and hypoxia. MRP1 function directly modulates intracellular drug concentrations, glutathione homeostasis, and lipid signaling. The transporter operates in concert with molecular partners such as glutathione (GSH), the glutathione synthesis enzyme GCLC, glutathione S-transferases (GST), and leukotriene C4 synthase. Additionally, its anchoring and regulation at the plasma membrane involve the actin cytoskeleton through interactions with ERM proteins (ezrin, radixin, moesin).
In the context of HT29 colorectal adenocarcinoma cells, ABCC1-mediated efflux is a critical determinant of chemotherapeutic resistance. The knockout model abrogates MRP1 function, leading to heightened intracellular accumulation of substrate drugs and a corresponding increase in drug sensitivity. This disruption also perturbs the efflux of endogenous metabolites, including glutathione conjugates and leukotrienes, thereby providing a unique tool for dissecting the contribution of MRP1 to metabolic and signaling pathways in colorectal cancer. The model is thus highly relevant for translational research into overcoming multidrug resistance in colorectal tumors.
Typical research applications include mechanistic studies of drug resistance, screening of chemosensitizers that target MRP1, substrate identification, and pharmacokinetic modeling of anticancer agents. The polyclonal knockout cells are compatible with a suite of assays such as the calcein-AM efflux assay to quantify transporter activity, MTT or ATP-based viability assays to assess drug sensitivity, LC-MS analysis for precise measurement of intracellular drug levels, and glutathione quantification. Gene expression analysis by RT-qPCR and protein detection via western blotting can be used to confirm ABCC1 disruption and monitor compensatory changes. For additional product details, technical support, or custom inquiries, please contact Ascent Research.
